← Back to Search

Neurokinin-1 Receptor Antagonist

Tradipitant for Motion Sickness

Phase 3
Recruiting
Research Sponsored by Vanda Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 18-75
Be older than 18 years old
Must not have
Nausea-inducing disorder other than motion sickness
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion, approximately 1 year
Awards & highlights

Summary

This trial is testing a medication called tradipitant to see if it can help people who get sick when they travel. The study includes both men and women who experience motion sickness. Tradipitant works by stopping the brain from sending signals that cause nausea and vomiting. Tradipitant has the potential to be an effective therapy for the prevention of vomiting and treatment of nausea in people with motion sickness.

Who is the study for?
This trial is for adults aged 18-75 who have a history of getting motion sickness. It's not suitable for individuals with other nausea-causing conditions, those with a BMI over 40, or anyone allergic to Neurokinin-1 Receptor antagonists.
What is being tested?
The study is testing the safety and effectiveness of Tradipitant in preventing or reducing symptoms of motion sickness during travel. This open label trial allows all participants to receive the medication.
What are the potential side effects?
Potential side effects may include drowsiness, dry mouth, headache, and possible gastrointestinal issues like constipation. Since it's an open label study, more side effects might be identified as participants report them.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 75 years old.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I have a condition that causes nausea, not including motion sickness.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion, approximately 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, approximately 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Safety and tolerability of tradipitant as measured by reporting of adverse events (AEs).

Side effects data

From 2019 Phase 3 trial • 375 Patients • NCT03568331
4%
Upper respiratory tract infection
4%
Headache
3%
Diarrhoea
2%
Dermatitis atopic
1%
Choking
1%
Dyshidrotic eczema
100%
80%
60%
40%
20%
0%
Study treatment Arm
Tradipitant
Placebo

Trial Design

2Treatment groups
Experimental Treatment
Group I: Tradipitant Dose BExperimental Treatment1 Intervention
"See Drug"
Group II: Tradipitant Dose AExperimental Treatment1 Intervention
"See Drug"
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Tradipitant
2021
Completed Phase 3
~1090

Research Highlights

Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.
Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
Tradipitant, an NK1 receptor antagonist, works by blocking the action of substance P, a neuropeptide involved in vomiting and nausea pathways. Common treatments for motion sickness include antihistamines (e.g., dimenhydrinate) that block H1 receptors to reduce vestibular system activity, and anticholinergics (e.g., scopolamine) that inhibit muscarinic receptors to prevent nausea signals from reaching the brain. Understanding these mechanisms is crucial for patients as it helps in selecting the most effective treatment based on their specific symptoms and potential side effects, ensuring better management of motion sickness.
The importance of systematic approaches in the study of emesis.

Find a Location

Who is running the clinical trial?

Vanda PharmaceuticalsLead Sponsor
62 Previous Clinical Trials
18,930 Total Patients Enrolled
3 Trials studying Motion Sickness
815 Patients Enrolled for Motion Sickness
~135 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top